Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The efficacy and safety of oral fluconazole versus a polyene regimen in preventing mycoses in neutropenic patients was compared. Patients with haematological malignancy or bone marrow transplantation received as antifungal prophylaxis either fluconazole 200 mg daily or a regimen consisting of clotrimazole trouches 10 mg twice daily with mycostatin, 500,000 i.u. four times daily, benadryl and cepacol mouthwash. Ninety patients at risk for fungus infection were evaluable. Four of 42 patients (9.5 %; confidence interval 2 %–23 %) on fluconazole and 17 of 48 patients (35.4 %; confidence interval 22 %–52 %) (p<0.01) on the clotrimazole regimen developed a clinically significant fungal infection, including 3 (7.1 %) and 11 (22.9 %) patients respectively who had severe fungal infection, mainly pulmonary aspergillosis. Death directly due to a fungal infection within 100 days of the start of prophylaxis occurred in 2 of 42 patients (4.8 %) and 9 of 48 patients (18.8 %) respectively (p<0.06). Kaplan-Meier analysis showed that the chance of survival on fluconazole was statistically greater than for the clotrimazole regimen (p<0.04). A decrease of candidal colonisation of the gastrointestinal and genitourinary tracts occurred only in patients receiving fluconazole. No significant toxicity occurred. A 200 mg daily dose of fluconazole given to these patients thus appears to be well tolerated and to provide a protective effect against the development of fungal infection and death from severe fungal disease.
- Meunier F Candidiasis. European Journal of Clinical Microbiology & Infectious Diseases 1989, 8: 438–447.
- Bodey GP Infection in cancer patients: a continuing association. American Journal of Medicine 1986, 81, Supplement 1A: 11–26. CrossRef
- Young RC, Bennett JE, Vogel CL, Carbone PP, DeVita VT Aspergillosis. The spectrum of the disease in 98 patients. Medicine 1970, 49: 147–173.
- Degregorio MU, Lee WM, Linker CA Fungal infections in patients with acute leukemia. American Journal of Medicine 1982, 73: 543–548. CrossRef
- Gross MH, Pickard WW, Perfect JR Retrospective review of amphotericin B use in a tertiary-care medical center. American Journal of Hospital Pharmacy 1987, 44: 1353–1357.
- Degregorio MU, Lee WM, Ries CA Candida infections in patients with acute leukemia: ineffectiveness of nystatin prophylaxis and relationship between oropharyngeal and systemic candidiasis. Cancer 1982, 50: 2780–2784.
- Donnelly JP, Starke ID, Galton DA, Catovsky D, Goldman JM, Darrell, JH Oral ketoconazole and amphotericin B for the prevention of yeast colonization in patients with acute leukaemia. Journal of Hospital Infection 1984, 5: 83–91. CrossRef
- Owens NJ, Nightingale CH, Schweizer RT, Schauer PK, Dekker PT, Quintiliani R Prophylaxis of oral candidiasis with clotrimazole troches. Archives of Internal Medicine 1984, 144: 290–293. CrossRef
- Meunier F Prevention of mycoses in immunocompromised patients. Reviews of Infectious Diseases 1987, 9: 408–416.
- Hann IM, Corringham R, Keaney M, Noone P, Fox J, Szawatkowski M, Prentice HG, Blacklock HA, Shannon M, Gascoigne E, Boesen E, Hoffbrand AV: Ketoconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely immunocompromised patients. Lancet 1982, 826–829.
- Grant SM, Clissold SP Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 1990, 39: 877–916.
- Aisner J, Schimpff SC, Wiernik PH Treatment of invasive aspergillosis: relation of early diagnosis and treatment to response. Annals of Internal Medicine 1977, 86: 539–543.
- Burch PA, Karp JE, Merz WG, Kuhlman JE, Fishman EK Favorable outcome of invasive aspergillosis in patients with acute leukemia. Journal of Clinical Oncology 1987, 5: 1985–1993.
- Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, Shadduck RK, Shea TC, Stiff P, Friedman DJ, Powderly WG, Silber JL, Horowitz H, Lightin A, Wolff SN, Mangan KF, Silver SM, Weisdorf D, Ho WG, Gilbert G, Buell D A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. New England Journal of Medicine 1992, 326: 845–851.
- Humphrey MJ, Jevons S, Tarbit MH Pharmacokinetic evaluation of UK 49858, a metabolically stable triazole antifungal in animals and humans. Antimicrobial Agents and Chemotherapy 1985, 28: 648–653.
- Troke PF, Andrews RJ, Marriott MS, Richardson K Efficacy of Fluconazole (UK-49,858) against experimental aspergillosis and cryptococcosis in mice. Antimicrobial Agents and Chemotherapy 1987, 19: 663–670.
- Patterson TF, George D, Miniter P andAndriole VT The role of fluconazole in the early treatment and prophylaxis of experimental invasive aspergillosis. Journal of Infectious Diseases 1991, 164: 575–580.
- Troke PF, Andrews RJ, Pye GW, Richardson K Fluconazole and other azoles: translation of in vitro activity to in vivo and clinical efficacy. Reviews of Infectious Diseases 1990, 12: 276–280.
- Verfaillie C, Weisdorf D, Haake R, Hostetter M, Ramsay N, McGlave P Candida infections in bone marrow transplant recipients. Bone Marrow Transplantation 1991, 8: 177–184.
- Wingard JR, Merg WG, Rinaldi MG, Johnson TR, Karf JE, Saral R Increase inCandida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. New England Journal of Medicine 1991, 18: 1274–1277.
- Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients
European Journal of Clinical Microbiology and Infectious Diseases
Volume 13, Issue 1 , pp 3-11
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Department of Medicine, King Faisal Specialist Hospital and Research Centre, 11211, Riyadh, Kingdom of Saudi Arabia
- 2. Department of Oncology, King Faisal Specialist Hospital and Research Centre, 11211, Riyadh, Kingdom of Saudi Arabia
- 3. Karolinska Hospital, Stockholm, Sweden
- 4. Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Centre, 11211, Riyadh, Kingdom of Saudi Arabia
- 5. University of Manchester Medical School, Manchester, UK
- 6. Biomedical Statistics and Scientific Computing Department, King Faisal Specialist Hospital and Research Centre, 11211, Riyadh, Kingdom of Saudi Arabia